Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of flt3 protein in the preparation of a kit for evaluating the efficacy of sorafenib in liver cancer

A therapeutic effect evaluation and kit technology, which is applied in the field of preparation of a kit for evaluating the curative effect of liver cancer against sorafenib, can solve problems such as no research reports on Flt3 protein, and achieve good prognosis

Active Publication Date: 2017-12-26
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no research report on the application of Flt3 protein in the preparation of sorafenib / curative effect evaluation kit after liver cancer surgery

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of flt3 protein in the preparation of a kit for evaluating the efficacy of sorafenib in liver cancer
  • Application of flt3 protein in the preparation of a kit for evaluating the efficacy of sorafenib in liver cancer
  • Application of flt3 protein in the preparation of a kit for evaluating the efficacy of sorafenib in liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Paraffin sections of liver cancer tissues from 89 liver cancer patients who did not take sorafenib after surgery were randomly selected (the liver cancer tissue sections were all from the Eastern Hepatobiliary Surgery Hospital and were diagnosed as hepatocellular carcinoma by 2 pathologists), and Flt3 was detected by immunohistochemical methods The expression level of protein in liver cancer tissue and calculate the immunohistochemical score, the specific steps are as follows:

[0057] (1) Prepare paraffin sections of liver cancer tissues in a 60°C oven overnight;

[0058] (2) Dewax slices to water;

[0059] (XyleneⅠ①10min→XyleneⅡ②10min→XyleneⅢ③10min→100% ethanol 5min→95% ethanol 5min→85% ethanol 5min→75% ethanol 5min→double distilled water 5min)

[0060] (3) 3%H 2 O 2 The solution is kept at room temperature for 20 minutes;

[0061] (4) Double-distilled water washing for 5min×3;

[0062] (5) Antigen retrieval: Put the slices into 0.01M citrate buffer (pH 6.0) and boil for 30 min...

Embodiment 2

[0079] Combined with the prognostic information, survival analysis was performed on liver cancer patients with low expression of Flt3 protein among the 182 patients in Example 1 (64 in the medication group and 55 in the drug-free group). The data analysis used SPSS software 18.0, and the survival curve analysis used the Kaplan-Meier method. , The log-rank test was used for comparison between the two groups. The results found that there was no statistical difference between the survival of patients with low Flt3 expression in the medication group and the patients with low Flt3 expression in the no medication group (P=0.187) (see figure 2 ). The results suggest that whether Sorafenib is taken in the Flt3 low expression group does not affect the prognosis of the patients.

Embodiment 3

[0081] Combined with the prognostic information, survival analysis was performed on the liver cancer patients with high Flt3 protein expression among the 182 patients in Example 1 (29 in the drug group and 34 in the drug-free group). Data analysis was performed using SPSS software 18.0, and survival curve analysis was performed using Kaplan-Meier method. , The log-rank test was used for comparison between the two groups. The results found that patients with high Flt3 expression in the medication group survived significantly better than those with high Flt3 expression in the untreated group. There was a statistical difference in survival analysis between the two groups (P=0.038) ( image 3 ). The results suggest that the Flt3 protein high expression group has a better prognosis after taking sorafenib.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the technical field of biology, particularly to applications of Flt3 protein in preparation of a kit for evaluating the liver cancer treating effect of sorafenib. According to the present invention, the discovery of the correlation between the Flt3 protein and the liver cancer provides a completely-new biological marker for the prediction of the treatment effect of the sorafenib taken by the liver cancer patient, and provides important guiding effects on whether the liver cancer patient takes the sorafenib; and the liver cancer patient with the high Flt3 protein expression is sensitive to the sorafenib treatment, is suitable for the treatment with sorafenib, and has the good prognosis after the treatment, such that the important guiding significance is provided for the use of the sorafenib by the liver cancer patient.

Description

Technical field [0001] The invention relates to the field of biotechnology, and relates to an application of Flt3 protein, specifically, the application of Flt3 protein in preparing a kit for evaluating the therapeutic effect of liver cancer on sorafenib. Background technique [0002] Liver cancer is currently one of the most common malignant tumors, and its morbidity and mortality have remained high for a long time. my country is the country with the largest incidence of liver cancer in the world. According to the "Announcement of the Latest Global Cancer Statistics" data, there are 782,000 new cases of liver cancer and 745,000 deaths worldwide each year. Among them, the number of new cases and deaths in China accounted for about 50%. [0003] In recent years, the application of molecular targeted drugs in the treatment of liver cancer has gradually received attention and is becoming a new hot spot. Sorafenib (Nexavar), a multi-target receptor tyrosine kinase inhibitor, is the o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574G01N33/573
CPCG01N33/573G01N33/57438G01N2333/912
Inventor 丁劲王红阳刘辉李晓峰程卓汪珍光
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com